Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Lewiecki, E Michael
  • Dinavahi, Rajani V
  • Lazaretti-Castro, Marise
  • Ebeling, Peter R
  • Adachi, Jonathan Derrick
  • Miyauchi, Akimitsu
  • Gielen, Evelien
  • Milmont, Cassandra E
  • Libanati, Cesar
  • Grauer, Andreas

publication date

  • December 1, 2017